Immuno-Modulatory Gene Polymorphisms and Outcome in Breast and Ovarian Cancer

Immunological Investigations

Volumn 38, Issue 3-4, 2009, Pages 324-340

  Kim, Sarah ^a   Hagemann, Andrea ^a   Demichele, Angela ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Perelman Center for Advanced Medicine   (United States)

Author keywords

Breast cancer; Cytokine; Ovarian cancer; Polymorphism

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE MARKER; COMPLEMENT COMPONENT C1Q; CYTOKINE; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; BREAST CANCER; CANCER SURVIVAL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GENETIC VARIABILITY; GRAFT VERSUS HOST REACTION; HOMOZYGOSITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; MEMORY T LYMPHOCYTE; MICROENVIRONMENT; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 70350633759     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130902910567     Document Type: Review

References (79)

1. Akhurst, R. J., Balmain, A. (1999). Genetic events and the role of TGF beta in epithelial tumour progression. J. Pathol. 187(1):82-90.
2. Alexandrakis, M. G., Passam, F. H., Perisinakis, K., et al. (2002). Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis. Respir. Med. 96(8):553-558.
3. Asgeirsson, K. S., Olafsdottir, K., Jonasson, J. G., et al. (1998). The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer. Cytokine 10(9):720-728.
4. Asschert, J. G., De Vries, E. G., De Jong, S., et al. (1999a). Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1. Int. J. Cancer 81(2):236-242.
5. Asschert, J. G., Vellenga, E., Ruiters, M. H., et al. (1999b). Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int. J. Cancer 82(2):244-249.
6. Badache, A., Hynes, N. E. (2001). Interleukin 6 inhibits proliferation and, in cooperation with an epiDermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res..61(1):383-391.
7. Bazzoni, F., Beutler, B. (1996). The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. 334(26):1717-1725. (Pubitemid 26193625)
8. BelarDelli, F., Ferrantini, M. (2002). Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23(4):201-208.
9. Benoy, I., Salgado, R., Colpaert, C., et al. (2002). Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin. Breast Cancer 2(4):311-315.
10. Bonafe, M., Olivieri, F., Cavallone, L. et al. (2001). A genDer-DepenDent genetic preDisposition to produce high levels of IL-6 is Detrimental for longevity. Eur. J. Immunol. 31(8):2357-2361.
11. Chang, C. F., Westbrook, R., Ma, J., et al. (2007). Transforming growth factor-beta signaling in breast cancer. Front Biosci. 124393-124401
12. Chaudhry, P., Srinivasan, R., Patel, F. D., et al. (2008). Serum soluble Fas levels and preDiction of response to platinum-based chemotherapy in epithelial ovarian cancer. Int. J. Cancer 122(8):1716-1721.
13. Conze, D., Weiss, L., Regen, P. S., et al. (2001). Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 61(24):8851-8858.
14. Coussens, L. M. Werb, Z. (2002). Inflammation and cancer. Nature 420(6917):860-867.
15. Crew, K. D., Gammon, M. D., Terry, M. B., et al. (2007). Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 28(12):2548-2551.
16. DeLarco, J. E., Wuertz, B. R., Rosner, K. A., et al. (2001). A potential role for interleukin-8 in the meastatic phenotype of breast carcinoma cells. Am. J. Pathol. 158:629.
17. DeMichele, A., Martin, A. M., Mick, R., et al. (2003). Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.Cancer Res. 63(22):8051-8056.
18. Desruisseau, S., Palmari, J., Giusti, C., et al. (2006). Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Br. J. Cancer 94(2):239-246.
19. Duan, J., SanDers, A. R., Molen, J. E., et al. (2003). Polymorphisms in the 5-untranslated region of the human serotonin receptor 1B (HTR1B) gene affect gene expression. Mol. Psych.. 8(11):901-910.
20. Fishman, D., Faulds, G., Jeffery, R., et al. (1998). The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 102(7): 1369-1376.
21. Garg, R., Wollan, M., Galic, V., et al. (2006). Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol. Oncol. 103(3):793-796.
22. Ghafoor, A., Jemal, A., Ward, E., et al. (2003). Trends in breast cancer by race and ethnicity. CA Cancer J. Clin. 53(6):342-355.
23. Gordon, M. A., Gil, J., Lu, B. (2006). Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoraDiation. Pharmacogenetics 7: 67-88.
24. Gutierrez, L. S., Eliza, M., Niven-Fairchild, T., et al. (1999). The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res. Treat 54(3):245-253.
25. Haukim, N., Bidwell, J. L., Smith, A. J., et al. (2002). Cytokine gene polymorphism in human Disease: on-line databases, supplement 2. Genes Immun. 3(6):313-330.
26. Hefler, L. A., Grimm, C., Ackermann, S., et al. (2003). An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 63(12):3066-3068.
27. Heim, M. H. (1999).The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res. 19(1-4):75-120.
28. Hempel, L., Korholz, D., Nussbaum, P., et al. (1997). High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transpl. 20(5):365-368.
29. Hess, A. D., Bright, E. C., Thoburn, C., et al. (1997). Specificity of effector T lymphocytes in autologous graft-versus-host Disease: role of the major histocompatibility complex class II invariant chain peptiDe. Blood 89(6):2203-2209.
30. Huang, Q. R., Morris, D., Manolios, N. (1997). IDentification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol. Immunol. 34(8-9):577-582.
31. Hulkkonen, J., Pertovaara, M., Antonen, J., et al. (2001). Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjogren's syndrome and correlate with the clinical manifestations of the Disease. Rheumatology 40(6):656-661.
32. Jemal, A., Murray, T., Ward, E., et al. (2005). Cancer statistics, 2005. CA Cancer J. Clin. 55(1):10-30.
33. Karja, V., Aaltomaa, S., Lipponen, P., et al. (2005). Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by raDical prostatectomy. Anticancer Res. 25(6C):4435-4438.
34. Kesari, A. L., Chellam, V. G., Mathew, B. S., et al. (1999). Transforming growth factor beta related to extent of tumor angiogenesis but not apoptosis or proliferation in breast carcinoma. Breast Cancer 6(1):29-36.
35. Kidd, P. (2003). Th1/Th2 balance: the hypothesis, its limitations, and implications for health and Disease. Altern. Med. Rev. 8(3):223-246.
36. Koch, A., Polverini, P. J., Kunkel, S. L., et al. (1992). interleukin-8 as a macrophage Derived meDiator of angiogenesis. Science 258: 1798.
37. Konno, R., Takano, T., Sato, S., et al. (2000). Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin. Cancer Res. 6(9): 3576-3580.
38. Lanzavecchia, A., Sallusto, F. (2001). Regulation of T cell immunity by Dendritic cells. Cell 106(3):263-266.
39. Leek, R. D., Harris, A. L. (2002). Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 7(2):177-189.
40. Lin, M. T., Juan, C. Y., Chang, K. J., et al. (2001). IL-6 inhibits apoptosis and retains oxidative DNA lesions in human gastric cancer AGS cells through up-regulation of anti-apoptotic gene mcl-1. Carcinogenesis 22(12):1947-1953.
41. Marrogi, A. J., Munshi,A., Merogi, A. J., et al. (1997). Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer 74(5):492-501.
42. Martin, A. M., AthanasiaDis, G., Greshock, J. D., et al. (2003). Population frequencies of single nucleotiDe polymorphisms (SNPs) in immuno-modulatory genes. Hum. Hered. 55(4):171-178.
43. McGuire, W. P., Markman, M., III (2003). Primary ovarian cancer chemotherapy: current standards of care. Br. J. Cancer 89 Suppl 3: S3-8.
44. McGuire, W. P., Brady, M. F., Ozols, R. F. (1999). The Gynecologic Oncology Group experience in ovarian cancer. Ann. Oncol. 10 Suppl 1: 29-34.
45. Mestiri, S., Bouaouina, N., Ahmed, S. B., et al. (2001). Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 91(4): 672-678.
46. Mestiri, S., Bouaouina, N., Ahmed, S. B., et al. (2005). A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse preDiction of breast carcinoma. Cytokine 30(4):182-187.
47. Miura, Y., Thoburn, C. J., Bright, E. C., et al. (2002). Cytokine and chemokine profiles in autologous graft-versus-host Disease (GVHD): interleukin 10 and interferon gamma may be critical meDiators for the Development of autologous GVHD. Blood 100(7):2650-2658.
48. Morita, C., Horiuchi, T., Tsukamoto, H., et al. (2001). Association of tumor necrosis factor receptor type II polymorphism 196R with systemic lupus erythematosus in the Japanese: molecular and functional analysis. Arthritis Rheumat. 44(12):2819-2827.
49. Mu, L., Katsaros, D., Lu, L., et al. (2008). TGF-beta1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. Br. J. Cancer 99(8):1357-1363.
50. Murray, P. A., Barrett-Lee, P., Travers, M., et al. (1993). The prognostic significance of transforming growth factors in human breast cancer. Br. J. Cancer 67(6):1408-1412.
51. Musselman, D. L., Miller, A. H., Porter, M. R., et al. (2001). Higher than normal plasma interleukin-6 concentrations in cancer patients with Depression: preliminary finDings. Am. J. Psych. 158(8):1252-1257.
52. Nishimura, R., Nagao, K., Miyayama, H., et al. (2000). An analysis of serum interleukin- 6 levels to preDict benefits of medroxyprogesterone acetate in adVanced or recurrent breast cancer. Oncology 59(2):166-173.
53. Petry, F., Loos, M. (2005). Common silent mutations in all types of hereDitary complement C1q Deficiencies. Immunogenetics 57(8):566-571.
54. Plante, M., Rubin, S. C., Wong, G. Y., et al. (1994). Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73(7):1882-1888.
55. Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4(1):71-78.
56. Purohit, A., Reed, M. J. (2002). Regulation of estrogen synthesis in postmenopausal women. Steroids 67(12):979-983.
57. Racila, E., Racila, D. M., Ritchie, J. M., et al. (2006). The pattern of clinical breast cancer metastasis correlates with a single nucleotiDe polymorphism in the C1qA component of complement. Immunogenetics 58(1):1-8.
58. Reiss, M., Barcellos-Hoff, M. H. (1997). Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45(1):81-95.
59. Salama, P., Phillips, M., Grieu, F., et al. (2009). Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27(2):186-192.
60. Salles, G., Bienvenu, J., Bastion, Y., et al. (1996). Elevated circulating levels of TNFalpha and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Br. J. Haematol. 93(2):352-359.
61. Sato, E., Olson, S. H., Ahn, J., et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102(51):18538-18543.
62. Scambia, G., Testa, U., BeneDetti Panici, P., et al. (1995). Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br. J. Cancer 71(2): 354-356.
63. Schultheis, A. M., Lurje, G., RhoDes, K. E., et al. (2008). Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamiDe and bevacizumab. Clin. Cancer Res.14(22):7554-7563.
64. Schumacher, K., Haensch, W., Roefzaad, C., et al. (2001). Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 61(10):3932-3936.
65. Singh, A., Purohit, A., Duncan, L. J., et al. (1997). Control of aromatase activity in breast tumours: the role of the immune system. J. Steroid Biochem. Molec. Biol. 61(3-6):185-192.
66. Smith, K. C., Bateman, A. C., Fussell, H. M., et al. (2004). Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur. J. Immunogenet. 31(4):167-173.
67. Terry, C. F., Loukaci, V., Green, F. R. (2000). Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J. Biol. Chem. 275(24): 18138-18144.
68. Turner, D. M., Williams, D. M., Sankaran, D., et al. (1997). An investigation of polymorphism in the interleukin-10 gene promoter. Eur. J. Immunogenet. 24(1):1-8.
69. Ueda, M., Hung, Y. C., Teraiet, Y., al. (2005). Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin. Cancer Res. 11(9):3225-3232.
70. Wakefield, L. M., Piek, E., Bottinger, E. P. (2001). TGF-beta signaling in mammary gland Development and tumorigenesis. J Mammary Gland Biol Neoplasia 6(1):67-82.
71. Warzocha, K., Ribeiro, P., Bienvenu, J., et al. (1998). Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91(10):3574-3581.
72. Wei, L. H., Kuo, M. L., Chen, C. A., et al. (2001). The anti-apoptotic role of interleukin-6 in human cervical cancer is meDiated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 20(41):5799-5809.
73. Wu, J., Metz, C., Xu, X., et al. (2003). A novel polymorphic CAAT/enhancer-binDing protein beta element in the FasL gene promoter alters Fas ligand expression: a canDidate background gene in African American systemic lupus erythematosus patients. J. Immunol. 170(1):132-138.
74. Wu, J. M., Bensen-Kennedy, D., Miura, Y., et al. (2005). The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer. Biol Blood Marrow Transplant 11(6):455-464.
75. Yokoe, T., Iino, Y., Morishita, Y. (2000). Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer 7(3):187-190.
76. Yokota, M., Ichihara, S., Lin, T. L., et al. (2000). Association of a T29->C polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to myocarDial infarction in Japanese. Circulation 101(24):2783-2787.
77. Zhang, B., Sun, T., Xue, L., et al. (2007). Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 28(5):1067-1073.
78. Zhang, G. J., Adachi, I. (1999). Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res. 19(2B):1427-1432.
79. Zhang, L., Conejo-Garcia, J. R., Katsaros, D., et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3):203-213.